Sigma-2 receptor as a potential therapeutic target for treating central nervous system disorders
Kazuki Terada
Keisuke Migita
Yukari Matsushima
Chiaki Kamei
摘要：The sigma receptor (Sig-R) was first reported by Martin et al. (1976) and was initially classified into the opioid receptor family. However, Sig-R was subsequently found to differ from the opioid receptor in various studies including ligand binding assays and autoradiography analysis (Tam and Cook, 1984). Sig-R is widely distributed in tissues such as central nervous, digestive, immune, and endocrine tissues. There are two types of Sig-R: sigma-1 (Sig-1R) and sigma-2 receptors (Sig-2R). Re-cent studies reported that each subtype has distinct cellular and physiological functions. Since Hanner et al. (1996) successfully cloned the Sig-1R gene, the functions of Sig-1R have been wide-ly evaluated in the fields of cell biology, molecular biology, can-cer, immunology, and behavioral neuroscience. Particularly, it has been suggested that Sig-1R activates neurons in the central nervous system (CNS) and contributes to physiological func-tions such as memory and cranial nerve protection. In contrast, Sig-2R has not been cloned. Sig-2R is thought to be involved in cellular processes related to neuropathy, as pharmacological studies suggested that Sig-2R is widely distributed in the CNS. Recently, Alon et al. (2017) identified the gene encoding Sig-2R. This perspective focuses on whether Sig-2R is useful as a ther-apeutic target for CNS disorders such as Alzheimer’s disease, Parkinson’s disease, and depression, based on the structure of Sig-2R and its role in nerve growth.
机标关键词：
资助基金：Japan Society for the Promotion of Science KAKENHI (JP16K18888)Japan Society for the Promotion of Science KAKENHI ( to KT)
论文发表日期：2019-01-01
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：2( 1893-1894 )